- 询价
- SignaGen
- 美国
- SignaGen
- 2026年01月03日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
4°C
- 库存：
现货 大量
- 供应商：
美中清水湾生物科技有限公司
Pre-packaged AAV:
All the following pre-packaged AAVs were pre-made with serotype 1**, 2, 5, 6, 8** and 9** as controls. All the pre-packaged rAAVs were titered via qPCR, packed in sterile PBS and in ready-to-use format.
|
Catalog # |
Product |
Titer |
Size * |
Price |
|
AAV-Null (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-miRNA(scramble)-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-Cre (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-Cre-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-GFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-mRFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-LacZ (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-YFP (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChIEF-tdTOMATO (Serotype 1) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Null (AAV Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-GFP (AAV Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-Cre (AAV Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-Cre-GFP (Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-GFP (Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-U6-miRNA(scramble)-GFP (Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-CAG-GFP (Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-CAG-Cre (Serotype 2) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-CAG-Cre-GFP (Serotype 2) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-GFP (Serotype 2) |
1x1012~1x1013 VG/ml |
100 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-tdTOMATO (Serotype 2) |
1x1012~1x1013 VG/ml |
100 μl |
$168 ~ $488 |
|
|
AAV-mRFP (Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-LacZ (Serotype 2) |
1x1012~1x1013 VG/ml |
200 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-YFP (Serotype 2) |
1x1012~1x1013 VG/ml |
100 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-tdTOMATO (Serotype 2) |
1x1012~1x1013 VG/ml |
100 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChIEF-tdTOMATO (Serotype 2) |
1x1012~1x1013 VG/ml |
100 μl |
$168 ~ $488 |
|
|
AAV-Null (AAV Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-GFP (AAV Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre (AAV Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre-GFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-GFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-miRNA(scramble)-GFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-GFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-GFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-RFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-mRFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-LacZ (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-YFP (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChIEF-tdTOMATO (Serotype 5) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
|
||||
|
AAV-Null (AAV Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-GFP (AAV Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-Cre (AAV Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-Cre-GFP (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-GFP (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-CAG-GFP (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-GFP (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-RFP (Serotype 6) |
> 1x1013 VG/ml |
> 20 μl |
$168 ~ $488 |
|
|
AAV-mRFP (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-LacZ (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-YFP (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChIEF-tdTOMATO (Serotype 6) |
> 1x1013 VG/ml |
> 30 μl |
$168 ~ $488 |
|
|
|
||||
|
AAV-Null (AAV Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-GFP (AAV Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre (AAV Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre-GFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-GFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-GFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-GFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-Cre (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-Cre-GFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-mRFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-LacZ (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-YFP (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChIEF-tdTOMATO (Serotype 8) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Null (AAV Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-GFP (AAV Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-GFP (AAV Serotype 9, Self-complementary) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre (AAV Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre (AAV Serotype 9, Self-complementary) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Cre-GFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-CMV-GFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-U6-shRNA(scramble)-EF1a-GFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-GFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-Cre-GFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-GFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-Cre (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-Synapsin-Cre-GFP (Serotype 9) |
&g, t;, 1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-mRFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-LacZ (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChR2-YFP (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-ChIEF-tdTOMATO (Serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
AAV-CAG-shRNA(scramble) (serotype 9) |
>1x1013 VG/ml |
>30 μl |
$168 ~ $488 |
|
|
|
||||
|
AAV Serotypes Testing Kit |
|
|
|
|
|
AAV Serotypes Testing Kit |
1x1012~1x1013 VG/ml |
6 x 200 μl |
$2342 |
|
* All our pre-made rAAVs are super purified (in vivo grade) via advanced CsCl ultra-centrifugation and Ok to inject directly to animals. The titer of pre-made rAAVs as determined via qPCR is highly dependent upon transgene and serotypes and varies from batch to batch. For standard packs, we offer >30 μl of pre-made rAAVs at >1E+13 VG/ml or >200 μl at >1E+12 VG/ml. For trial packs, we offer >10 μl of pre-made rAAVs at >1E+13 VG/ml or >70 μl at >1E+12 VG/ml.
** Some terms may apply to purchase of certain serotype of pre-packaged AAVs.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验一、技术背景： Adeasy 系统利用了腺病毒具有的高感染能力，可高度浓缩等优点，并破坏了腺病毒基因组中的早期基因E1，使之成为较为安全、高效的病毒载体。利用带有E1 基因的293 细胞作为包装细胞，通过倍比扩增，富集病毒颗粒，并通过CsCl 梯度离心，透析进行分离纯化。对绝大多数的细胞株可以达到近乎100％的感染效率。但需要指出的是Adeasy 同样具有所有病毒载体或转染试剂都不可避免的细胞毒性问题。 二、所需试剂： 1. 293 细胞；2. 重组好的腺病毒质粒；3. Pac
收集病毒。按步骤1收集细胞并准备病毒上清。通过Western blot和/或PCR鉴定重组腺病毒产生。 4、PCR鉴定重组病毒。取5μl病毒上清加入10μl蛋白酶K，55℃孵育1hr,再煮沸5min，离心后取1-2μl作PCR。 五、重组病毒扩增，纯化 1、75cm2方瓶中接种293细胞，至密度达到90%,加入适量病毒上清感染细胞。3-4d后，细胞几乎变圆，且有一半细胞漂浮，则收集所有细胞。约500g转速离心，弃上清。 2、以灭菌PBS重悬沉淀，反复冻融4次。4℃下7000g离心5min
1 腺病毒的包装，纯化和感染 技术背景：Adeasy 系统利用了腺病毒具有的高感染能力，可高度浓缩等优点， 并破坏了腺病毒基因组中的早期基因E1，使之成为较为安全、高效的病毒载体。 利用带有E1 基因的293 细胞作为包装细胞，通过倍比扩增，富集病毒颗粒，并 通过CsCl 梯度离心，透析进行分离纯化。对绝大多数的细胞株可以达到近乎100 ％的感染效率。但需要指出的是Adeasy 同样具有所有病毒载体或转染试剂都不 可避免的细胞毒性问题。 所需试剂：
技术资料暂无技术资料 索取技术资料
